Granulocyte-macrophage colony-stimulating factor (GM-CSF)–secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML)

Preclinical models have demonstrated the efficacy of granulocyte-macrophage colony-stimulating factor-secreting cancer immunotherapies (GVAX platform) accompanied by immunotherapy-primed lymphocytes after autologous stem cell transplantation in hematologic malignancies. We conducted a phase 2 study...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Borrello, Ivan M., Levitsky, Hyam I., Stock, Wendy, Sher, Dorie, Qin, Lu, DeAngelo, Daniel J., Alyea, Edwin P., Stone, Richard M., Damon, Lloyd E., Linker, Charles A., Maslyar, Daniel J., Hege, Kristen M.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Hematology 2009
נושאים:
Clinical Trials and Observations
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC2738565/
https://ncbi.nlm.nih.gov/pubmed/19556425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-02-205278
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים